Table 1. Cytotoxicity (IC50/μM, 72 h treatment) of the Pt(ii) complexes towards HeLa, breast cancer (MDA), ovarian carcinoma (A2780), nasopharyngeal carcinoma (SUNE1), B16 melanoma, hepatocellular carcinoma cells (HepG2) and non-tumorigenic immortalized liver cells (MIHA) a .
| Entry | HeLa | MDA | A2780 | SUNE1 | B16 | HepG2 | MIHA |
| 1a | 4.4 ± 0.6 | 1.6 ± 0.4 | 1.2 ± 0.1 | 3.5 ± 0.8 | 0.66 ± 0.04 | 1.3 ± 0.1 | 6.36 ± 0.15 |
| 1b | 2.8 ± 0.2 | 2.1 ± 0.5 | 1.2 ± 0.1 | 2.8 ± 0.6 | 0.42 ± 0.02 | 1.7 ± 0.4 | 5.23 ± 0.62 |
| 2 | 5.1 ± 1.1 | 5.0 ± 0.2 | 3.3 ± 0.2 | 4.4 ± 1.0 | 0.85 ± 0.07 | 4.0 ± 0.8 | 8.12 ± 1.27 |
| 3 | 3.8 ± 0.5 | 4.2 ± 1.0 | 2.7 ± 0.1 | 3.9 ± 0.7 | 2.6 ± 0.2 | 2.7 ± 0.2 | 9.56 ± 2.15 |
| 4 | 8.3 ± 0.9 | 7.4 ± 0.5 | 5.0 ± 0.2 | 7.9 ± 1.3 | 3.0 ± 0.3 | 6.2 ± 0.6 | 13.51 ± 2.12 |
| 5 | 14.4 ± 3.5 | 8.3 ± 1.6 | 11.7 ± 2.1 | 12.3 ± 4.2 | 6.2 ± 0.5 | 9.0 ± 1.6 | 20.15 ± 2.92 |
| Cisplatin | 7.9 ± 1.2 | 25.0 ± 1.4 | 3.9 ± 0.8 | 9.7 ± 2.8 | 15.1 ± 0.9 | 48.2 ± 6.5 | 58.8 ± 6.1 |
aThe IC50 values are determined by at least three independent assays.